_______________________________________________________________________________________________________________ As the demands of clinical development continue to intensify and the need for speed and precision grows ever greater, hVIVO has firmly positioned itself as a purpose-built innovator for the future of modern drug development. Combining full-service early phase CRO capabilities with world-leading human challenge trial expertise, hVIVO delivers decisive human data that enables biopharma and emerging biotech companies to move from strategy to clinical proof-ofconcept faster and with greater certainty.
With dedicated teams, A-list laboratories, study recruitment, consultancy, and biobanking within a single operational model, hVIVO is streamlining drug development pathways whilst reducing complexity and risk. As the organization continues to broaden its horizons, Manufacturing Today sits down with Dr. Andrew Catchpole, Chief Scientific Officer at hVIVO, to learn more about the driving forces behind the company’ s operational strength and uncover its most recent developments.
“ The business started back in 1989. At that point, it was solely a lab business testing HIV drugs, initially called Retroscreen Virology,” Andrew begins, providing insight into hVIVO’ s background.“ Back in the late 1980s, HIV was a massive research field, so we saw big pharma take a lot of that research internal. We started focusing on influenza and soon became specialists in that, and, in 2000, we started doing human viral challenge studies, where we deliberately recruit and inoculate healthy volunteers with a virus to study the effects of vaccines or antiviral drugs. Those studies have quickly become one of the main revenue earners of the business. We’ ve since become world-renowned for conducting commercial challenge studies, and we’ re now using our clinical expertise to expand into other disciplines.”
Building upon its existing success, hVIVO has continued to broaden both its
78